利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.015 秒)

    Cap-dependent endonuclease inhibitors
    2.
    发明授权
    Cap-dependent endonuclease inhibitors 有权

    公开(公告)号：US10596171B2

    公开(公告)日：2020-03-24

    申请号：US16251652

    申请日：2019-01-18

    申请人： TaiGen Biotechnology Co., Ltd. ,  Ming-Chu Hsu

    发明人： Chu-Chung Lin ,  Hung-Chuan Chen ,  Chiayn Chiang ,  Chi-Feng Yen ,  Ming-Chu Hsu

    IPC分类号： A61K31/5025 ,  A61P31/16

    摘要： Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5′R6′ or NR7′; each of R1, R2, R2′, R3, R3′, R4, R5, R5′, R6, R6′, R7, and R7′, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5′ and R6′, or R5 and R5′, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.

    CAP-DEPENDENT ENDONUCLEASE INHIBITORS
    5.
    发明申请
    CAP-DEPENDENT ENDONUCLEASE INHIBITORS 审中-公开

    公开(公告)号：US20190224198A1

    公开(公告)日：2019-07-25

    申请号：US16251652

    申请日：2019-01-18

    申请人： Ming-Chu Hsu ,  TaiGen Biotechnology Co., Ltd.

    发明人： Chu-Chung Lin ,  Hung-Chuan Chen ,  Chiayn Chiang ,  Chi-Feng Yen ,  Ming-Chu Hsu

    IPC分类号： A61K31/5025 ,  A61P31/16

    CPC分类号： A61K31/5025 ,  A61P31/16

    摘要： Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5′R6′ or NR7′; each of R1, R2, R2′, R3, R3′, R4, R5, R5′, R6, R6′, R7, and R7′, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5′ and R6′, or R5 and R5′, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.